CA3060702A1 - Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration - Google Patents

Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration Download PDF

Info

Publication number
CA3060702A1
CA3060702A1 CA3060702A CA3060702A CA3060702A1 CA 3060702 A1 CA3060702 A1 CA 3060702A1 CA 3060702 A CA3060702 A CA 3060702A CA 3060702 A CA3060702 A CA 3060702A CA 3060702 A1 CA3060702 A1 CA 3060702A1
Authority
CA
Canada
Prior art keywords
pharmaceutical agent
antiarrhythmic
antiarrhythmic pharmaceutical
class
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3060702A
Other languages
English (en)
French (fr)
Inventor
Carlos Schuler
Rangachari Narasimhan
Luiz Belardinelli
Prashanti MADHAVAPEDDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incarda Therapeutics Inc
Original Assignee
Madhavapeddi Prashanti
Incarda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madhavapeddi Prashanti, Incarda Therapeutics Inc filed Critical Madhavapeddi Prashanti
Publication of CA3060702A1 publication Critical patent/CA3060702A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Engineering (AREA)
CA3060702A 2017-05-10 2018-05-10 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration Pending CA3060702A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504292P 2017-05-10 2017-05-10
US62/504,292 2017-05-10
PCT/US2018/032092 WO2018209107A1 (en) 2017-05-10 2018-05-10 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Publications (1)

Publication Number Publication Date
CA3060702A1 true CA3060702A1 (en) 2018-11-15

Family

ID=64096874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3060702A Pending CA3060702A1 (en) 2017-05-10 2018-05-10 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Country Status (9)

Country Link
US (5) US10441537B2 (https=)
EP (1) EP3621616A4 (https=)
JP (2) JP2020519628A (https=)
KR (1) KR20200003199A (https=)
CN (1) CN110869018A (https=)
AU (1) AU2018266199A1 (https=)
CA (1) CA3060702A1 (https=)
IL (1) IL270407B2 (https=)
WO (1) WO2018209107A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114847965A (zh) 2016-02-01 2022-08-05 英凯达治疗公司 电子监测联合吸入药理学疗法管理心律失常
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
KR102891439B1 (ko) 2019-08-01 2025-11-25 인카다 테라퓨틱스, 인크. 항부정맥 제제
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN111595112B (zh) * 2020-05-26 2022-02-08 内蒙古铂贝曼科技有限公司 一种粉末磷脂的制备方法
US20230233545A1 (en) * 2020-06-15 2023-07-27 MyoKardia, Inc. Treatment of atrial dysfunction
AU2021400335A1 (en) 2020-12-17 2023-06-22 Incarda Therapeutics, Inc. Kits and methods for induction of cardioversion in subjects with atrial arrhythmias
CN116867483A (zh) * 2020-12-17 2023-10-10 英凯达治疗公司 用于诱导患有房性心律失常的对象的心脏复律的试剂盒和方法
US20240252431A1 (en) * 2021-07-20 2024-08-01 Onconox Inc. Pulmonary biguanide formulations and delivery devices

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001029A (en) 1911-01-03 1911-08-22 Paul E Herrmann Hair-curler.
US1004593A (en) 1911-03-25 1911-10-03 Catherine Ryan Measuring device for cutting garments.
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
SE408265B (sv) 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
US4930518A (en) 1988-09-26 1990-06-05 Hrushesky William J M Sinus arrhythmia monitor
US4962095A (en) 1989-02-15 1990-10-09 E. R. Squibb & Sons, Inc. Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5364880A (en) * 1993-06-16 1994-11-15 Advanced Therapies, Inc. Compound for treatment of cardiac arrhythmia, synthesis, and methods of use
NZ281112A (en) 1994-03-07 1998-04-27 Inhale Therapeutic Syst Powdered insulin delivered as an aerosol
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
JP3388896B2 (ja) 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6077543A (en) 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
CN1169520C (zh) 1997-09-29 2004-10-06 耐科塔医药公司 多孔微粒及其使用方法
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6541479B1 (en) 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
DE69935154T2 (de) 1998-11-12 2007-10-25 Inc. Transave Inhalationssystem
EP1181069B1 (en) 1999-05-28 2006-06-28 Nektar Therapeutics Apparatus and method for aerosolising a powder pharmaceutical composition
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6357490B1 (en) 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
CA2432319A1 (en) 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
WO2002080859A2 (en) 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20080038363A1 (en) 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP4795637B2 (ja) 2001-09-28 2011-10-19 カーブ テクノロジー，インコーポレイティド 鼻ネブライザー
ATE418991T1 (de) 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US8245708B2 (en) 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
EP1515768B1 (en) 2002-05-07 2013-11-06 The State University of New York at Stony Brook Devices for targeted endobronchial therapy
US20040045546A1 (en) 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
TR200502522T2 (tr) 2002-12-31 2005-09-21 Nektar Therapeutics Çözünmez bir aktif madde içeren farmasötik formülasyon
MXPA05011428A (es) 2003-04-24 2006-05-31 Aderis Pharmaceuticals Inc Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
WO2005018635A2 (en) 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7967756B2 (en) 2003-09-18 2011-06-28 Cardiac Pacemakers, Inc. Respiratory therapy control based on cardiac cycle
WO2005079897A1 (en) 2004-02-25 2005-09-01 Resmed Limited Cardiac monitoring and therapy using a device for providing pressure treatment of sleep disordered breathing
CA2464029A1 (en) 2004-04-08 2005-10-08 Valery Telfort Non-invasive ventilation monitor
CN101001633A (zh) 2004-05-21 2007-07-18 特兰萨夫公司 肺病和肺病前期病症的治疗
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20060120962A1 (en) 2004-10-12 2006-06-08 Rabinowitz Joshua D Cardiac safe, rapid medication delivery
TWI396541B (zh) 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
JP4931930B2 (ja) 2005-10-21 2012-05-16 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャネル阻害剤
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
RU2463085C2 (ru) 2006-10-25 2012-10-10 Новартис Аг Аппарат для распыления порошка, способ его изготовления и применения и его компоненты
EP2099295A4 (en) 2006-11-22 2010-02-24 Reliant Pharmaceuticals Inc PROPHYLAXIS AND TREATMENT OF AURICULAR FIBRILLATION WITH OMEGA-3 FATTY ACIDS
TW200840578A (en) 2006-12-15 2008-10-16 Procter & Gamble Compositions of azimilide dihydrochloride
WO2008134630A1 (en) 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20080275036A1 (en) 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
CN101467968A (zh) 2007-12-24 2009-07-01 浙江正方医药科技有限公司 抗心律失常药物的新给药途径的制剂
US20110144125A1 (en) 2008-08-14 2011-06-16 The Uab Research Foundation Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore
US8501727B2 (en) 2008-08-22 2013-08-06 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof
CA2778604C (en) 2008-09-23 2021-10-05 Laboratory Skin Care, Inc. Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same
AU2013248242B2 (en) * 2009-03-18 2016-08-18 Incarda Therapeutics, Inc Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2016256776B2 (en) 2009-03-18 2018-04-12 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
ITRM20110390A1 (it) 2011-07-21 2013-01-22 Eramo Alessandra D Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione.
CN114847965A (zh) 2016-02-01 2022-08-05 英凯达治疗公司 电子监测联合吸入药理学疗法管理心律失常

Also Published As

Publication number Publication date
US20200179278A1 (en) 2020-06-11
IL270407B1 (en) 2023-11-01
IL270407B2 (en) 2024-03-01
US10441537B2 (en) 2019-10-15
EP3621616A4 (en) 2021-01-13
JP2020519628A (ja) 2020-07-02
KR20200003199A (ko) 2020-01-08
IL270407A (https=) 2020-01-30
US20180325818A1 (en) 2018-11-15
US20190083396A1 (en) 2019-03-21
AU2018266199A1 (en) 2019-11-07
CN110869018A (zh) 2020-03-06
EP3621616A1 (en) 2020-03-18
US20200179279A1 (en) 2020-06-11
WO2018209107A1 (en) 2018-11-15
US20230092389A1 (en) 2023-03-23
JP2023100743A (ja) 2023-07-19

Similar Documents

Publication Publication Date Title
US20230092389A1 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA2835771C (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2022202842B2 (en) Antiarrhythmic formulation
AU2013248242B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US11007185B2 (en) Antiarrhythmic formulation
AU2016256776B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40025425A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220912

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241104

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250304

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251029

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251229